Anavex Life Sciences Corp (OTCMKTS:AVXL) confirmed the election of Dr. Steffen Thomas, PhD, to its Board. Dr. Thomas holds both PhD as well as MS degrees in Chemistry earned from the University of Munich.
The highlights
Dr. Thomas has 15 years of experience handling matters related to patent law, intellectual law and proprietary technology rights. He has extensive proficiency in small molecule pharmaceuticals. He is associated with Epping Hermann Fischer as a European trademark advocate, a patent lawyer and European patent attorney.
Epping is a European intellectual property law firm. Earlier, Dr. Thomas was associated with Takeda Pharmaceutical Company. Prior to that, he worked with Nycomed Pharma, which was later acquired by Takeda for almost USD $10 billion.
The highlights
Anavex reported that Dr. Thomas’ legal practice covers preparing of patent applications, questioning patent applications before patent offices, defending and challenging patents in nullity, opposition and plea cases. It also contains enforcing patents in front of the violation courts, and making opinions on violation and patentability in the technical section of chemistry.
The CEO Christopher U. Missling, PhD, stated that they are pleased to have Dr. Thomas on the Board. They are of view that Dr. Thomas’ insight on pharmaceutical industry and expertise in intellectual property will be tremendously helpful as Anavex Life is moving forward its product pipeline.
The changes
The recent appointment is the second major appointment announced by the company in past few months. In March, Jacqueline French, MD, FAAN was included in Scientific Advisory Board. Since the release of important Press Releases Anavex Life Sciences Corp (OTCMKTS:AVXL) stock price has been moving north on the charts.
On Monday’s trading session, the stock price of AVXL gained more than 9% to close the trading session at $0.450.The gains came at a share volume of 3.20 million compared to average share volume of 1.24 million.
